Evidence map›Paper›PMID 31713006›Full record

ArticleAAPS PharmSciTech2019

Wurster Fluidised Bed Coating of Microparticles: Towards Scalable Production of Oral Sustained-Release Liquid Medicines for Patients with Swallowing Difficulties.

Valentyn Mohylyuk, Kavil Patel, Nathan Scott, Craig Richardson, Darragh Murnane, Fang Liu

Open access · hybridAbstract read
In one paragraph

Article in AAPS PharmSciTech, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
5.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Development and Characterization of Microparticles withAntioxidants (Basel, Switzerland) · 2023
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Valentyn MohylyukDepartment of Clinical and Pharmaceutical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, UK.
Kavil PatelDepartment of Clinical and Pharmaceutical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, UK.
Nathan ScottDepartment of Clinical and Pharmaceutical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, UK.
Craig RichardsonFluid Pharma Ltd., Nexus, Discovery Way, Leeds, LS2 3AA, UK.
Darragh MurnaneDepartment of Clinical and Pharmaceutical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, UK.
Fang LiuDepartment of Clinical and Pharmaceutical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, UK. f.liu3@herts.ac.uk.
4D Pharma (United Kingdom) · GBUniversity of Hertfordshire · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Suspension of microparticles in an easy-to-swallow liquid is one approach to develop sustained-release formulations for children and patients with swallowing difficulties. However, to date production of sustained-release microparticles at the industrial scale has proven to be challenging. The aim of this investigation was to develop an innovative concept in coating sustained-release microparticles using industrial scalable Wurster fluidised bed to produce oral liquid suspensions. Microcrystalline cellulose cores (particle size <150 μm) were coated with Eudragit® NM 30 D and Eudragit® RS/RL 30 D aqueous dispersions using a fluidised bed coater. A novel approach of periodic addition of a small quantity (0.1% w/w) of dry powder glidant, magnesium stearate, to the coating chamber via an external port was applied throughout the coating process. This method significantly increased coating production yield from less than 50% to up to 99% compared to conventional coating process without the dry powder glidant. Powder rheology tests showed that dry powder glidants increased the tapped density and decreased the cohesive index of coated microparticles. Reproducible microencapsulation of a highly water-soluble drug, metoprolol succinate, was achieved, yielding coated microparticles less than 200 μm in size with 20-h sustained drug release, suitable for use in liquid suspensions. The robust, scalable technology presented in this study offers an important solution to the long-standing challenges of formulating sustained-release dosage forms suitable for children and older people with swallowing difficulties.

Indexed as

Administration, OralNanoparticlesAgedCelluloseChildDeglutition DisordersDelayed-Action PreparationsDrug CompoundingExcipientsHumansMetoprololParticle SizePolymethacrylic AcidsPowdersRheologyStearic AcidsCelluloseDelayed-Action PreparationsExcipientsmethylmethacrylate-methacrylic acid copolymerMetoprololmicrocrystalline cellulosePolymethacrylic AcidsPowdersstearic acidStearic AcidsControlled releaseDysphagiaGeriatricMultiparticulatesPaediatric

Identifiers

PMID31713006
PMCPMC6848247
OpenAlexW2988928266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.